Plecanatide

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Plecanatide is an oral analog of uroguanylin, a peptide involved in intestinal fluid regulation. By activating guanylate cyclase-C, it increases fluid secretion and supports bowel movement in adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. [1]

02 Potential benefits

Activates guanylate cyclase-C in the intestine. Approved for defined chronic constipation disorders. [1]

03 Evidence & its limits

Severe diarrhea is a recognized risk. TRULANCE is contraindicated below age six because of serious dehydration risk, and its label advises avoiding use from six through seventeen. Known or suspected mechanical gastrointestinal obstruction is also a contraindication. [1]

04 Risks & unknowns

Diarrhea is the principal adverse effect. Pediatric contraindications and age restrictions matter. [1]

05 Status & scope

Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA Drugs@FDA database
[3] MedlinePlus: medication-specific uses and precautions
[4] TRULANCE prescribing information

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.